Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigations

Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein

Anna Orlova, Andreas Jonsson, Daniel Rosik, Hans Lundqvist, Malin Lindborg, Lars Abrahmsen, Caroline Ekblad, Fredrik Y. Frejd and Vladimir Tolmachev
Journal of Nuclear Medicine June 2013, 54 (6) 961-968; DOI: https://doi.org/10.2967/jnumed.112.110700
Anna Orlova
1Preclinical PET Platform, Medicinal Chemistry, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Jonsson
2Division of Molecular Biotechnology, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Rosik
2Division of Molecular Biotechnology, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Lundqvist
3Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malin Lindborg
4Affibody AB, Solna, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Abrahmsen
4Affibody AB, Solna, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Ekblad
4Affibody AB, Solna, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fredrik Y. Frejd
3Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; and
4Affibody AB, Solna, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Tolmachev
3Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 54 no. 6 961-968
DOI 
https://doi.org/10.2967/jnumed.112.110700
PubMed 
23528382

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication July 1, 2012
  • Accepted for publication November 27, 2012
  • Published online June 3, 2013.

Article Versions

  • previous version (March 25, 2013 - 05:19).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Anna Orlova1,
  2. Andreas Jonsson2,
  3. Daniel Rosik2,
  4. Hans Lundqvist3,
  5. Malin Lindborg4,
  6. Lars Abrahmsen4,
  7. Caroline Ekblad4,
  8. Fredrik Y. Frejd3,4 and
  9. Vladimir Tolmachev3
  1. 1Preclinical PET Platform, Medicinal Chemistry, Uppsala University, Uppsala, Sweden
  2. 2Division of Molecular Biotechnology, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden
  3. 3Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; and
  4. 4Affibody AB, Solna, Sweden
  1. For correspondence or reprints contact: Anna Orlova, Dag Hammarskjöldsv 14C, 3 tr, 751 83 Uppsala, Sweden.E-mail: anna.orlova{at}pet.medchem.uu.se
View Full Text

Statistics from Altmetric.com

Cited By...

  • 74 Citations
  • 74 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Harnessing albumin as a carrier for cancer therapies
    Ella N. Hoogenboezem, Craig L. Duvall
    Advanced Drug Delivery Reviews 2018 130
  • Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications
    Sharmila Banerjee, M. R. A. Pillai, F. F. (Russ) Knapp
    Chemical Reviews 2015 115 8
  • Half-life extended biotherapeutics
    Roland E. Kontermann
    Expert Opinion on Biological Therapy 2016 16 7
  • Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics
    Alessandro Zorzi, Sara Linciano, Alessandro Angelini
    MedChemComm 2019 10 7
  • Engineered Protein Scaffolds as Next-Generation Therapeutics
    Michaela Gebauer, Arne Skerra
    Annual Review of Pharmacology and Toxicology 2020 60 1
  • THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING
    Johan Nilvebrant, Sophia Hober
    Computational and Structural Biotechnology Journal 2013 6 7
  • Diabody Pretargeting with Click Chemistry In Vivo
    Sander M.J. van Duijnhoven, Raffaella Rossin, Sandra M. van den Bosch, Michael P. Wheatcroft, Peter J. Hudson, Marc S. Robillard
    Journal of Nuclear Medicine 2015 56 9
  • Half-life extension using serum albumin-binding DARPin® domains
    Daniel Steiner, Frieder W Merz, Ivo Sonderegger, Maya Gulotti-Georgieva, Denis Villemagne, Douglas J Phillips, Patrik Forrer, Michael T Stumpp, Christof Zitt, H Kaspar Binz
    Protein Engineering, Design and Selection 2017 30 9
  • Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL
    Rui Li, Hao Yang, Dianlong Jia, Qianxue Nie, Huawei Cai, Qing Fan, Lin Wan, Lin Li, Xiaofeng Lu
    Journal of Controlled Release 2016 228
  • Bioconjugation – using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers
    Smita B. Gunnoo, Annemieke Madder
    Organic & Biomolecular Chemistry 2016 14 34

Article usage

Article usage: March 2013 to April 2025

AbstractFullPdf
Mar 2013162018
Apr 2013285036
May 2013107022
Jun 20136451263
Jul 2013204521
Aug 2013921316
Sep 2013951920
Oct 2013662020
Nov 2013481316
Dec 2013562223
Jan 2014571618
Feb 2014471626
Mar 2014331517
Apr 2014321419
May 2014922318
Jun 2014461612
Jul 2014362622
Aug 2014201412
Sep 2014342114
Oct 2014351816
Nov 2014283327
Dec 2014262015
Jan 2015282020
Feb 201530127
Mar 2015561912
Apr 201539114
May 2015702026
Jun 201524197
Jul 2015134327
Aug 2015261313
Sep 2015182215
Oct 2015192021
Nov 2015272011
Dec 2015462315
Jan 2016561213
Feb 2016181512
Mar 2016241622
Apr 201630919
May 2016261117
Jun 2016272115
Jul 20162597
Aug 2016161014
Sep 2016121513
Oct 2016291118
Nov 201622118
Dec 2016161311
Jan 2017273213
Feb 201715169
Mar 2017342512
Apr 20179143
May 2017161514
Jun 201722114
Jul 20178108
Aug 2017982
Sep 2017121310
Oct 2017321519
Nov 20172052
Dec 2017291716
Jan 20181077
Feb 20182515416
Mar 2018272746
Apr 20182923514
May 201821229
Jun 20188196
Jul 2018612918
Aug 20188148
Sep 201815140
Oct 201816277
Nov 201821235
Dec 20185336
Jan 20199283
Feb 201916239
Mar 2019262912
Apr 201917238
May 2019131115
Jun 2019141218
Jul 201910218
Aug 201913148
Sep 20192559
Oct 20191247
Nov 201911109
Dec 20191537
Jan 20201932
Feb 20209911
Mar 20203099
Apr 2020536
May 202021814
Jun 20201349
Jul 20209611
Aug 202014814
Sep 20202159
Oct 20201447
Nov 2020171114
Dec 202026711
Jan 2021102413
Feb 2021141817
Mar 2021142620
Apr 202182417
May 202182014
Jun 202161712
Jul 2021142334
Aug 202152217
Sep 202162220
Oct 202172731
Nov 202183033
Dec 202132010
Jan 202271817
Feb 20227259
Mar 2022124226
Apr 202283823
May 202264232
Jun 20222309
Jul 202273516
Aug 2022152822
Sep 202252821
Oct 202232520
Nov 202233415
Dec 20223177
Jan 2023183115
Feb 202362616
Mar 2023146316
Apr 202363526
May 202372320
Jun 202362814
Jul 202392713
Aug 2023143628
Sep 202367710
Oct 202379724
Nov 2023313225
Dec 202364813
Jan 2024126122
Feb 2024265219
Mar 202452531
Apr 2024311823
May 202474833
Jun 2024102721
Jul 202473323
Aug 202464526
Sep 2024122219
Oct 2024154537
Nov 202494019
Dec 202473318
Jan 2025111826
Feb 202587919
Mar 2025135528
Apr 202576332
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 54 (6)
Journal of Nuclear Medicine
Vol. 54, Issue 6
June 1, 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein
Anna Orlova, Andreas Jonsson, Daniel Rosik, Hans Lundqvist, Malin Lindborg, Lars Abrahmsen, Caroline Ekblad, Fredrik Y. Frejd, Vladimir Tolmachev
Journal of Nuclear Medicine Jun 2013, 54 (6) 961-968; DOI: 10.2967/jnumed.112.110700

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein
Anna Orlova, Andreas Jonsson, Daniel Rosik, Hans Lundqvist, Malin Lindborg, Lars Abrahmsen, Caroline Ekblad, Fredrik Y. Frejd, Vladimir Tolmachev
Journal of Nuclear Medicine Jun 2013, 54 (6) 961-968; DOI: 10.2967/jnumed.112.110700
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Structure-activity analysis of truncated albumin-binding domains suggests new lead constructs for potential therapeutic delivery
  • Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging
  • Diabody Pretargeting with Click Chemistry In Vivo
  • An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein
  • Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
  • Google Scholar

More in this TOC Section

  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
  • Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy
  • Design and Fabrication of Kidney Phantoms for Internal Radiation Dosimetry Using 3D Printing Technology
Show more Basic Science Investigations

Similar Articles

Keywords

  • HER2
  • Affibody molecule
  • 177Lu
  • targeting therapy
  • albumin
SNMMI

© 2025 SNMMI

Powered by HighWire